Alternative Endpoints in Phase III Trials Don’t Always Mean Boosts to OS, QOL

MedPage Today) — CHICAGO — Late-phase trials that showed superiority for an experimental intervention on a surrogate endpoint did not necessarily lead to improvements in overall survival (OS) or quality of life (QOL), according to a meta-epidemiologic…